Riluzole in Huntington's Disease

Autores
Categoría Estudio primario
Registro de estudiosClinicalTrials.gov
Año 2006

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
Cargando información sobre las referencias
Primary objective:

* The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington\'s Disease Rating Scale (UHDRS) as well as (3) the increase of a combined score of these.

Secondary objectives:

Secondary objectives are to assess

* changes in the other UHDRS subscales
* the number of patients who need antichoreic treatment and the time until this treatment has to be initiated
* the safety/tolerability of riluzole in Huntington patients
Epistemonikos ID: 1498b6469a543c11825d3797fb3bf443028d9343
First added on: Mar 30, 2022